Blood Res.  2022 Sep;57(3):244-246. 10.5045/br.2022.2022128.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis (CVST): a case report from Malaysia

• Liam CCK
• Tee YJ
• Boo YL
• Lim YS
• Shamsuddin AR
• Lim SM

• KMID: 2533255
• DOI: http://doi.org/10.5045/br.2022.2022128

Figure

• 

  Fig. 1 Contrast-enhanced CT brain and venography identified the presence of sagittal sinus (red arrow), torcula Herophili (green arrow), right and left transverse (orange and blue arrow) and left sigmoid sinus thrombosis.

Reference

1. Greinacher A, Langer F, Makris M, et al. 2022; Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J Thromb Haemost. 20:149–56. DOI: 10.1111/jth.15572. PMID: 34693641. PMCID: PMC8646430.

2. Schultz NH, Sørvoll IH, Michelsen AE, et al. 2021; Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 384:2124–30. DOI: 10.1056/NEJMoa2104882. PMID: 33835768. PMCID: PMC8112568.

3. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. 2021; Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 384:2092–101. DOI: 10.1056/NEJMoa2104840. PMID: 33835769. PMCID: PMC8095372.

4. Scully M, Singh D, Lown R, et al. 2021; Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 384:2202–11. DOI: 10.1056/NEJMoa2105385. PMID: 33861525. PMCID: PMC8112532.

5. Pavord S, Scully M, Hunt BJ, et al. 2021; Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 385:1680–9. DOI: 10.1056/NEJMoa2109908. PMID: 34379914.

6. Boonyawat K, Angchaisuksiri P. 2022; Vaccine-induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV-19 is rare in Asia. Res Pract Thromb Haemost. 6:e12644. DOI: 10.1002/rth2.12644. PMID: 35071968. PMCID: PMC8760608. PMID: b10dc7fe07da4a2eb6f4b3b0e8fdfcd5.

7. Lee LH, Gallus A, Jindal R, Wang C, Wu CC. 2017; Incidence of venous thromboembolism in Asian populations: a systematic review. Thromb Haemost. 117:2243–60. DOI: 10.1160/TH17-02-0134. PMID: 29212112.

8. Boonyawat K, Angchaisuksiri P, Aryurachai K, Chaiyaroj S, Ahmadi Z, Chong BH. 2014; Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients. Thromb Res. 134:957–62. DOI: 10.1016/j.thromres.2014.08.020. PMID: 25204999.

9. National Pharmaceutical Regulatory Agency, Ministry of Health, Malaysia. 2022. Summary report on adverse events following immunisation of COVID-19 vaccines in Malaysia. National Pharmaceutical Regulatory Agency (NPRA);Petaling Jaya, Malaysia: at https://www.npra.gov.my/index.php/en/. Accessed April 20, 2022.

10. Rizk JG, Gupta A, Sardar P, et al. 2021; Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiol. 6:1451–60. DOI: 10.1001/jamacardio.2021.3444. PMID: 34374713.

11. Klok FA, Pai M, Huisman MV, Makris M. 2022; Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 9:e73–80. DOI: 10.1016/S2352-3026(21)00306-9. PMID: 34774202. PMCID: PMC8585488.

12. Arepally GM, Ortel TL. 2021; Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood. 138:293–8. DOI: 10.1182/blood.2021012152. PMID: 34323940. PMCID: PMC8172307.